Insider Trading May 27, 2026 07:34 PM

Arteris Director Sells Significant Block of Shares Amid Positive Sector Developments

Wayne Cantwell's transactions follow strong Q1 results and major contract wins, highlighting increased interest in AI and automotive technologies.

By Caleb Monroe AIP

Director Wayne C. Cantwell of Arteris, Inc. (NASDAQ:AIP) sold a notable quantity of company stock on May 26, 2026, totaling approximately $1.43 million. This transaction occurs amidst several positive developments for the firm, including strong first-quarter financial reporting and significant technology integrations within the automotive sector. Furthermore, industry analysts have recently upgraded their price targets for Arteris shares.

Arteris Director Sells Significant Block of Shares Amid Positive Sector Developments
AIP

Key Points

  • Insider selling by director Wayne C. Cantwell
  • Strong Q1 financial results (EPS and revenue beats)
  • Major IP integration with Li Auto Inc. in the automotive sector

Wayne C. Cantwell, who serves as a director at Arteris, Inc., executed a sale of company stock on May 26, 2026. Specifically, Mr. Cantwell disposed of 38,500 shares of Arteris's common stock. The aggregate value of these transactions reached approximately $1,433,166.

Analysis of the sale reveals that the individual shares were transacted at prices ranging from a low of $36.79 to a high of $37.55. These sales resulted in a weighted average price for the shares sold, which was calculated at $37.2251.


Following this divestment, Mr. Cantwell's remaining holdings reflect both indirect and direct ownership structures. Through The Cantwell Living Trust, where he acts as trustee, his indirect stake in Arteris common stock amounts to 189,698 shares. Additionally, his direct ownership comprises 34,732 shares. A third component of his holding is an additional 38,761 shares held indirectly through the Decathlon Capital Management 401K Plan FBO Wayne Cantwell.


Market Context and Valuation Indicators

The timing of this insider sale has been noted in relation to current market valuation perspectives. Specifically, an analysis conducted by InvestingPro suggests that Arteris may be trading at an elevated level relative to its intrinsic value. This perceived overvaluation is a factor that could potentially have influenced the decision behind the recent insider transactions.

For those seeking deeper insights into Arteris's valuation metrics and comprehensive corporate analysis, investors are directed toward the detailed Pro Research Report. This report provides granular data not only on AIP but also covers over 1,400 other US equities.


Recent Corporate Milestones Driving Interest

The market attention surrounding Arteris is bolstered by several recent positive corporate developments. In a notable financial update, Arteris Inc. reported robust financial results for the first quarter of 2026. The company surpassed various expectations in its reporting.

  • Financial Performance: For Q1 2026, Arteris achieved an earnings per share (EPS) of -$0.03. This figure was favorable compared to the forecast, which had projected -$0.07 for the same period.
  • Revenue Growth: The company also exceeded anticipated revenue levels, reporting $22.94 million when analysts had expected a minimum of $21.03 million.

Beyond financial metrics, Arteris has secured significant technological partnerships within major industries. Li Auto Inc., for example, has integrated Arteris's system IP technology into its L9 Livis SUV model. The collaboration is set to continue in future vehicle generations.

This deployment involves the utilization of specific technologies developed by Arteris, including the FlexNoC 5 NoC interconnect IP and the Magillem SoC integration automation software designed for autonomous driving systems-on-chip. These integrations underscore the company's growing footprint in both the artificial intelligence (AI) and automotive sectors.


Analyst Sentiment and Price Target Adjustments

Investor confidence has been further signaled by professional analysts. TD Cowen recently elevated its price target for Arteris shares, revising it from $22 up to $40. Concurrently, the firm maintained a

Risks

  • Perceived overvaluation of Arteris stock according to InvestingPro analysis
  • Reliance on future guidance for second quarter and full year 2026

More from Insider Trading

Oscar Health Executive Victoria Baltrus Liquidates Shares Under Pre-Arranged Plan Jun 4, 2026 Lincoln Educational Director Felecia Pryor Offloads $99,400 in Stock Jun 4, 2026 Arm Holdings Chief Accounting Officer Executes $4.4 Million Share Sale Amid Market Surge Jun 4, 2026 Spire Director Paul Koonce Expands Equity Stake with $40,250 Share Purchase Jun 4, 2026 MIAX Executive Shelly Brown Executes $673,920 Stock Sale Under Pre-Arranged Plan Jun 4, 2026